RNA-BOUND: THE FUTURE OF ANTISENSE DRUGS

    loading  Checking for direct PDF access through Ovid

Abstract

♦ The use of nucleic acid therapies to block RNA function was first described in 1978, and rapidly progressed to the development of a variety of antisense agents.

♦ The latest generation of these compounds, based on synthetic RNA or RNA analogues, are said to be overcoming the main obstacle to success of their predecessors - their greater ability to bind with RNA.

♦ Among the third generation antisense drugs, Acuity Pharmaceuticals has the most advanced siRNA program, with its bevasiranib slated to begin Phase III trials next year for the treatment of wet age-related macular degeneration.

Related Topics

    loading  Loading Related Articles